ASCO-GU 2023
Feb 16 - 18, 2023 | San Francisco, CA
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
A Phase 2 Expansion Study of ARV-766, a PROTAC Androgen Receptor (AR) Degrader, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)DP Petrylak et al.